Loading…
← CockpitCompetitor Analysis › 088350.KS Hanwha LifeOpen in the cockpit ↗

Hanwha Life088350.KSCompetitor analysis, valuation and peers

South Korea · KRW·Financials›Life/Health Insurance

Hanwha Group's life insurer, offering life, health and pension products to Korean retail and corporate customers.

Momentum weak 32
Mkt cap
$2.09B
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$7.06M
20-day average traded
P/B
0.23×
price to book
ROE
4.6%
delivered
Implied ROE
3.8%
what the price asks
Next earnings
98 days
24 Feb 2027
Close · KRW₩3,690
1D+0.5%
1W-6.3%
1M-20.3%
3M-34.5%
6M-32.8%
YTD+13.4%
1Y+17.9%
ATR %5.1%
52w lowhigh51.2% off high

What Hanwha Life does

Hanwha Group's life insurer, offering life, health and pension products to Korean retail and corporate customers.

Earns from premiums on life, health and pension policies and from investing those premiums, keeping the difference between what it earns and what it credits to policyholders. Sold through its own agents, bank counters and corporate clients. It belongs to Hanwha Group, a Korean family-led conglomerate (chaebol).

Products and services

  • Life insurance
  • Health/medical insurance
  • Pension/annuity products
  • Asset management

Customers

  • Retail policyholders
  • Corporate group insurance clients

Where it sits in the supply chain

  • Insurance
  • Life and health insurance
  • Retail/corporate distribution

What could go right

  • Aging-population pension/health demand
  • Investment-portfolio yield recovery

What could go wrong

  • Low interest-rate/insurance-liability duration risk
  • Regulatory capital (K-ICS) requirements

Moat: narrow (scale, brand, distribution). One of Korea's largest life insurers with a broad agent/bancassurance distribution network.

Headquarters: Seoul, South Korea · Founded: 1946 · Employees: 2,794

Named competitors

Hanwha Life at a glance

Size Hanwha Life (088350.KS) is a South Korea Financials company (Life/Health Insurance) with a market value of $2.09B, the 137th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩3,690 on 18 Nov 2026.

Performance Over six months the shares fell 32.8%, against -7.2% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 18 in its peer set.

Growth Revenue grew 20.4% over the last twelve months (peer median +17.5%); the operating margin is 17.0% (peer median 5.9%).

Valuation It trades at 0.23× book value against a peer median of 1.95× (2nd cheapest of 18).

Price implies The share price implies a return on equity of about 3.8%; Hanwha Life delivers 4.6%, so the price asks less than the business earns today.

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 92088350.KS 68
Six months, rebased to 100: Hanwha Life against the median of its 17 peers (local-currency closes).

Hanwha Life financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩22.0T₩16.3T₩14.2T₩11.3T₩9.52T
Revenue growth—+15%+26%+19%—
Net income₩516B₩527B₩709B₩721B₩942B
Free cash flow-₩554B₩3.66T₩4.05T₩1.20T₩2.56T
Capital expenditure₩395B₩304B₩313B₩138B₩136B
Total debt₩34.7T₩31.2T₩14.6T₩11.7T₩11.6T

Quarterly statements and history in the cockpit →

Hanwha Life competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%-10%0%+10%CLOVBHF085620NBG6NIVABUPA002423PRVASTARHEALTHELF0376MFSLCGF7157ICICILIFE5859088350.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Hanwha Life is the large dot.

Fundamentals: return on equity against price-to-book

0%10%20%30%40%00×2.50×50×7.50×CLOVBHF085620NBG6NIVABUPA002423PRVACANHLIFESTARHEALTHELF0376MFSLCGF7157ICICILIFESTJ088350.KSReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Hanwha Life is the large dot.

Capital: ROE delivered against the ROE the price implies

0%20%40%60%80%0%25%50%75%CLOVBHF085620NBG6NIVABUPAPRVACANHLIFESTARHEALTHELFMFSLCGFICICILIFE5859STJ088350.KSROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Hanwha Life is the large dot.

Hanwha Life competitors and peer comparison

Head to head with its named competitors (088350.KS vs 032830.KS vs 085620.KS vs 082640.KS)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
Hanwha Life 088350.KS$2.09B-33%+20%5%0.23×3.8%
Samsung Life 032830.KS$34.1B-23%+33%4%0.37×5.0%
Mirae Asset Life Insurance 085620.KS$1.70B+19%+152%2%1.06×5.8%
TongYang Life Insurance 082640.KSn/a+19%n/an/an/an/a

How Hanwha Life compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hanwha Life against its 17 peers (data as of 18 Nov 2026)
Measure088350.KSPeer medianRank in peer set
1-month return-20.3%-0.5%lowest of 18
6-month return-32.8%-7.2%lowest of 18
Return on equity4.6%7.6%5th lowest of 18
Price / book0.23×1.95×2nd cheapest of 18
Trailing P/E5.4×25.8×4th cheapest of 18
ROE the price implies3.8%15.5%2nd least demanding of 18
ROE delivered4.6%7.6%5th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Hanwha Life 088350.KSSouth Korea$2.09B-33%+20%5%0.23×3.8%4.6%
Clover Health Investments CLOVUnited States$2.21B+16%+54%3%5.31×81.1%3.4%
Brighthouse Financial BHFUnited States$2.42B-33%-9%12%0.48×6.0%12.0%
Mirae Asset Life Insurance 085620.KSSouth Korea$1.70B+19%+152%2%1.06×5.8%1.8%
Nuernberger Beteiligungs NBG6.DEGermany$1.55B+2%-1%5%1.58×6.1%5.1%
Niva Bupa Health Insurance NIVABUPA.NSIndia$1.46B-9%+58%14%3.55×32.5%13.9%
COFCO Capital 002423.SZChina$3.08B-7%-31%6%0.83×6.1%5.6%
Privia Health PRVAUnited States$3.14B+6%+19%5%3.85×25.7%4.6%
Canara HSBC Life Insurance CANHLIFE.NSIndia$1.29B-8%+17%8%7.36×50.5%8.2%
Star Health & Allied Insurance STARHEALTH.NSIndia$3.53B+8%+21%12%3.16×47.6%11.7%
E-L Financial ELF.TOCanada$4.65B+15%+32%20%0.69×6.5%20.2%
Yunfeng Financial 0376.HKHong Kong$872M-24%+21%7%0.53×7.4%6.7%
Max Financial Services MFSL.NSIndia$5.25B-12%+18%3%8.53×87.5%3.3%
Challenger CGF.AXAustralia$5.26B+28%-25%13%1.95×15.5%13.3%
Lifenet Insurance 7157.TJapan$652M-28%+11%8%1.11×7.0%7.6%
ICICI Life Insurance ICICILIFE.NSIndia$6.90B-15%-8%13%4.72×66.2%12.6%
Farglory Life Insurance 5859.TWOTaiwan$614M-1%-48%7%0.22×1.7%7.1%
St. James's Place STJ.LUnited Kingdom$7.12B-10%+164%38%3.55×42.8%38.4%

Questions

Who are Hanwha Life's main competitors?
Named competitors: Samsung Life Insurance (032830.KS), Mirae Asset Life Insurance (085620.KS), Tongyang Life Insurance (082640.KS). The cockpit's measured peer set (industry) also includes Clover Health Investments (CLOV), Brighthouse Financial (BHF), Mirae Asset Life Insurance (085620.KS), Nuernberger Beteiligungs (NBG6.DE), Niva Bupa Health Insurance (NIVABUPA.NS), COFCO Capital (002423.SZ).
Is Hanwha Life expensive compared with its peers?
On price / book it trades at 0.23× against a peer median of 1.95×, 2nd cheapest of 18 in its peer set. The share price implies a return on equity of about 3.8%; Hanwha Life delivers 4.6%, so the price asks less than the business earns today.
How has Hanwha Life stock performed?
Over six months to 18 Nov 2026 the shares returned -32.8% against -7.2% for the median peer; over one year +17.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.